You are currently viewing a beta version of our website. If you spot anything unusual, kindly let us know.
Preprint
Review
Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers in Meningioma
Altmetrics
Downloads
225
Views
285
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Abstract
Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinase (RTKs), including those of the ErbB family of receptors, as oncogenes has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB 1), as well as other members of the ErbB family, may be useful as biomarkers in MGM.
Keywords:
Subject: Medicine and Pharmacology - Oncology and Oncogenics
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Submitted:
22 July 2021
Posted:
23 July 2021
You are already at the latest version
Alerts
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
22 July 2021
Posted:
23 July 2021
You are already at the latest version
Alerts
Abstract
Meningioma (MGM) is the most common type of intracranial tumor in adults. The validation of novel prognostic biomarkers to better inform tumor stratification and clinical prognosis is urgently needed. Many molecular and cellular alterations have been described in MGM tumors over the past few years, providing a rational basis for the identification of biomarkers and therapeutic targets. The role of receptor tyrosine kinase (RTKs), including those of the ErbB family of receptors, as oncogenes has been well established in several cancer types. Here, we review histological, molecular, and clinical evidence suggesting that RTKs, including the epidermal growth factor receptor (EGFR, ErbB 1), as well as other members of the ErbB family, may be useful as biomarkers in MGM.
Keywords:
Subject: Medicine and Pharmacology - Oncology and Oncogenics
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis
Liverana Lauretti
et al.
JPM,
2022
Prognostic Impact of Low-Level p53 Expression on Brain Astrocytomas Immunopositive for Epidermal Growth Factor Receptor
Hung-Pei Tsai
et al.
CIMB,
2022
Differential Expression and Clinical Significance of Transforming Growth Factor-Beta Isoforms in GBM Tumors
Laurent-Olivier Roy
et al.
IJMS,
2018
MDPI Initiatives
Important Links
© 2024 MDPI (Basel, Switzerland) unless otherwise stated